| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hendzel MJ | |
| Kaufmann SH | |||
| Patel A | |||
| Poirier GG | |||
| Rouleau M | |||
| P2860 | cites work | Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo | Q24294689 |
| Protein requirements for sister telomere association in human cells | Q24298717 | ||
| Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling | Q24316697 | ||
| Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1 | Q24321560 | ||
| Zinc binding catalytic domain of human tankyrase 1 | Q24328797 | ||
| XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage | Q24522502 | ||
| Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase) | Q24533586 | ||
| Understanding and treating triple-negative breast cancer | Q24620957 | ||
| High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | Q24644255 | ||
| Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler | Q24655668 | ||
| In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs) | Q24816599 | ||
| A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation | Q27649201 | ||
| Domain C of human poly(ADP-ribose) polymerase-1 is important for enzyme activity and contains a novel zinc-ribbon motif | Q27650500 | ||
| Poly (ADP-Ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain | Q70201918 | ||
| Possible model of liver carcinogenesis using inhibitors of NAD+ ADP ribosyl transferase in rats | Q70324936 | ||
| ADP-ribosyl protein lyase. Purification, properties, and identification of the product | Q71260762 | ||
| ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA | Q71364375 | ||
| ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites | Q71512084 | ||
| Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular | Q72571229 | ||
| Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks | Q40390945 | ||
| Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. | Q40529875 | ||
| Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks. | Q40880071 | ||
| Alkylating DNA damage stimulates a regulated form of necrotic cell death | Q40903823 | ||
| PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. | Q41867379 | ||
| Macromolecular association of ADP-ribosyltransferase and its correlation with enzymic activity | Q41971604 | ||
| Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure | Q42015817 | ||
| Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats | Q42242310 | ||
| Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture | Q42277843 | ||
| PARP-1 is involved in autophagy induced by DNA damage. | Q42806537 | ||
| Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation | Q43671893 | ||
| Studies on the polymer of adenosine diphosphate ribose. I. Enzymic formation from nicotinamide adenine dinuclotide in mammalian nuclei | Q43880697 | ||
| Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly (ADP-ribose) polymerase | Q43884373 | ||
| Studies on poly (adenosine diphosphate-ribose). X. Properties of a partially purified poly (adenosine diphosphate-ribose) polymerase | Q44141588 | ||
| Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci | Q44288764 | ||
| Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks | Q44800025 | ||
| Poly(ADP-ribose) polymerase inhibits DNA synthesis initiation in the absence of NAD. | Q46000177 | ||
| Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis | Q46086573 | ||
| Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer | Q46163448 | ||
| To die or to live: the dual role of poly(ADP-ribose) polymerase-1 in autophagy and necrosis under oxidative stress and DNA damage | Q46165802 | ||
| Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes | Q46258328 | ||
| A novel function of poly(ADP-ribose) polymerase-1 in modulation of autophagy and necrosis under oxidative stress. | Q46272227 | ||
| New functions for an ancient domain | Q47443515 | ||
| Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. | Q52535087 | ||
| Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. | Q54062885 | ||
| Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis | Q58326911 | ||
| (ADP-ribose)n participates in DNA excision repair | Q59086284 | ||
| DNA strand breaks and ADP-ribosyl transferase activation during cell differentiation | Q59093885 | ||
| Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition | Q63383833 | ||
| Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition | Q64388338 | ||
| Role of DNA breaks and ADP-ribosyl transferase activity in eukaryotic differentiation demonstrated in human lymphocytes | Q67238258 | ||
| A shuttle mechanism for DNA-protein interactions. The regulation of poly(ADP-ribose) polymerase | Q67244835 | ||
| Polymerization of the adenosine 5'-diphosphate ribose moiety of NAD by rat liver nuclear enzyme | Q68569352 | ||
| Characterization of polymers of adenosine diphosphate ribose generated in vitro and in vivo | Q70186032 | ||
| Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3 | Q27654592 | ||
| A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation | Q27657009 | ||
| Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888 | Q27659098 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner | Q28206417 | ||
| Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length | Q28207709 | ||
| Resistance to therapy caused by intragenic deletion in BRCA2 | Q28268169 | ||
| Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease | Q28298870 | ||
| PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase | Q28511873 | ||
| Generation and characterization of telomere length maintenance in tankyrase 2-deficient mice | Q28590926 | ||
| Tankyrase 2 poly(ADP-ribose) polymerase domain-deleted mice exhibit growth defects but have normal telomere length and capping | Q28593281 | ||
| Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage | Q28609805 | ||
| Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers | Q28645733 | ||
| PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways | Q29616041 | ||
| Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions | Q29617672 | ||
| AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy | Q29618101 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| Hypermetabolism, hyperphagia, and reduced adiposity in tankyrase-deficient mice | Q30434277 | ||
| PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites | Q33306325 | ||
| Tankyrase 1 and tankyrase 2 are essential but redundant for mouse embryonic development | Q33350164 | ||
| Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. | Q33403458 | ||
| Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells | Q33553364 | ||
| Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? | Q33944812 | ||
| Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme | Q33971109 | ||
| Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments | Q33979291 | ||
| 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. | Q34013829 | ||
| Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. | Q34017159 | ||
| PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression | Q34183985 | ||
| The PARP superfamily | Q34335821 | ||
| Role of poly(ADP-ribose) formation in DNA repair | Q34359946 | ||
| Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase | Q34466221 | ||
| The Nudix hydrolase superfamily | Q34479614 | ||
| Toward specific functions of poly(ADP-ribose) polymerase-2. | Q34763353 | ||
| PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA | Q39430828 | ||
| Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors | Q39782128 | ||
| Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential | Q39924656 | ||
| Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. | Q39928899 | ||
| Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. | Q39929975 | ||
| Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications | Q39946012 | ||
| Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. | Q39971672 | ||
| A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia | Q39985428 | ||
| The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity | Q40093906 | ||
| Purification and properties of poly(adenosine diphosphate ribose) synthetase | Q40099536 | ||
| Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models | Q40132595 | ||
| ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models | Q40138516 | ||
| Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents | Q40146768 | ||
| Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. | Q40158513 | ||
| Poly(ADP-ribose) levels in carcinogen-treated cells | Q40276647 | ||
| PolyADP-ribosylation is required for long-term memory formation in mammals | Q34994979 | ||
| Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse | Q35018839 | ||
| PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes. | Q35040007 | ||
| Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase | Q35271750 | ||
| Parthanatos, a messenger of death | Q35670138 | ||
| Poly(ADP-ribose) (PAR) polymer is a death signal | Q35722332 | ||
| Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice | Q35748808 | ||
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors | Q36042091 | ||
| A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage | Q36119231 | ||
| Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure | Q36297600 | ||
| Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors | Q36426742 | ||
| Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells | Q36654891 | ||
| Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology | Q36749057 | ||
| Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation | Q36842905 | ||
| Tankyrase function at telomeres, spindle poles, and beyond. | Q36933991 | ||
| PARP inhibitor development for systemic cancer targeting | Q36952027 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. | Q36992615 | ||
| Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes | Q37014677 | ||
| Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity | Q37089235 | ||
| Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. | Q37121130 | ||
| Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ | Q37124359 | ||
| Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines | Q37216709 | ||
| Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites | Q37235363 | ||
| Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90 | Q37309929 | ||
| Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns | Q37323035 | ||
| PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. | Q37334922 | ||
| Drug resistance caused by reversion mutation | Q37346915 | ||
| Novel enzyme from rat liver that cleaves an ADP-ribosyl histone linkage | Q37585955 | ||
| The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA. | Q37738852 | ||
| A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor | Q38279200 | ||
| Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes | Q38293731 | ||
| Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. | Q38335120 | ||
| Structural and biophysical studies of human PARP-1 in complex with damaged DNA. | Q38348304 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 293-301 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | PARP inhibition: PARP1 and beyond | |
| P478 | volume | 10 |
| Q51191211 | 14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2. |
| Q92591248 | 25-Hydroxycholesterol protects against myocardial ischemia-reperfusion injury via inhibiting PARP activity |
| Q60947426 | 3-Aminobenzamide Blocks MAMP-Induced Callose Deposition Independently of Its Poly(ADPribosyl)ation Inhibiting Activity |
| Q36052193 | 5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1. |
| Q36129160 | 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells |
| Q33739161 | A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity |
| Q47115127 | A Cell-Line-Specific Atlas of PARP-Mediated Protein Asp/Glu-ADP-Ribosylation in Breast Cancer |
| Q36432567 | A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer |
| Q91769921 | A PARP1-BRG1-SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites |
| Q53043418 | A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. |
| Q89490008 | A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study |
| Q24298137 | A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway |
| Q60955766 | A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models |
| Q48128057 | A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors |
| Q33580224 | A murine preclinical syngeneic transplantation model for breast cancer precision medicine. |
| Q90169827 | A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice |
| Q64255367 | A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer |
| Q35836463 | A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas |
| Q33415790 | A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report |
| Q34029054 | A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells |
| Q50249070 | A poly(ADP-ribose) polymerase-1 activity assay based on the FRET between a cationic conjugated polymer and supercharged green fluorescent protein |
| Q37130712 | A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. |
| Q33617275 | A type I IFN-dependent DNA damage response regulates the genetic program and inflammasome activation in macrophages |
| Q38758230 | ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells |
| Q58699862 | ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts |
| Q40140289 | ADP-Ribosylated Peptide Enrichment and Site Identification: The Phosphodiesterase-Based Method. |
| Q90597122 | ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers |
| Q38189514 | ADP-ribosylation: activation, recognition, and removal |
| Q37556937 | ADPriboDB: The database of ADP-ribosylated proteins. |
| Q36637370 | AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6. |
| Q27323759 | Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1 |
| Q35632602 | Aberrantly expressed mRNAs and long non-coding RNAs in patients with invasive ductal breast carcinoma: a pilot study |
| Q42422374 | Activator-induced spread of poly(ADP-ribose) polymerase promotes nucleosome loss at Hsp70. |
| Q55105639 | Advances in the systemic treatment of triple-negative breast cancer. |
| Q34597741 | Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases |
| Q27003972 | Advances in using PARP inhibitors to treat cancer |
| Q89637079 | Alkyladenine DNA glycosylase deficiency uncouples alkylation-induced strand break generation from PARP-1 activation and glycolysis inhibition |
| Q34037211 | Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. |
| Q36945357 | Altered DNA base excision repair profile in brain tissue and blood in Alzheimer's disease |
| Q91859979 | An Advanced Strategy for Comprehensive Profiling of ADP-ribosylation Sites Using Mass Spectrometry-based Proteomics |
| Q91967403 | An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein |
| Q44000570 | An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer |
| Q36102008 | An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. |
| Q49926243 | Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species |
| Q36248794 | Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. |
| Q57072237 | Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells |
| Q37800273 | Apoptosis assays for quantifying the bioactivity of anticancer drug products |
| Q37479268 | Arsenite binding-induced zinc loss from PARP-1 is equivalent to zinc deficiency in reducing PARP-1 activity, leading to inhibition of DNA repair |
| Q28389761 | Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs |
| Q90692765 | Assessment of Genotoxicity in Human Cells Exposed to Modulated Electromagnetic Fields of Wireless Communication Devices |
| Q28382839 | Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis |
| Q34603025 | Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells |
| Q43755302 | BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. |
| Q47250551 | BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer |
| Q99608808 | BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications |
| Q33930051 | BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation |
| Q36347042 | BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer |
| Q36224769 | BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer |
| Q36651488 | Balancing repair and tolerance of DNA damage caused by alkylating agents |
| Q35882620 | Base excision repair and design of small molecule inhibitors of human DNA polymerase β. |
| Q41552855 | Base excision repair imbalance in colorectal cancer has prognostic value and modulates response to chemotherapy |
| Q38435967 | Best practice in the treatment of advanced squamous cell lung cancer |
| Q26852274 | Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors |
| Q28480504 | Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOS |
| Q37851027 | Bioengineering approaches to study multidrug resistance in tumor cells |
| Q38769860 | Biological measures to minimize the risk of radiotherapy-associated second cancer: A research perspective |
| Q39641100 | Bioorthogonal small-molecule ligands for PARP1 imaging in living cells. |
| Q64374900 | Biphasic Functional Interaction between the Adenovirus E4orf4 Protein and DNA-PK |
| Q39665532 | Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity |
| Q35142790 | Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors |
| Q90737255 | Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape |
| Q44226295 | Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). |
| Q36580923 | CHFR is important for the first wave of ubiquitination at DNA damage sites |
| Q35921557 | CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation |
| Q91736519 | CHK2-mediated regulation of PARP1 in oxidative DNA damage response |
| Q35961020 | Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade |
| Q37376022 | Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells. |
| Q58101650 | Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival |
| Q34110442 | Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil |
| Q26796673 | Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine |
| Q39330291 | Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. |
| Q38714046 | Cis-Nerolidol Induces Endoplasmic Reticulum Stress and Cell Death in Human Hepatocellular Carcinoma Cells through Extensive CYP2C19 and CYP1A2 Oxidation. |
| Q34502009 | Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer |
| Q38038489 | Clinical trials and future potential of targeted therapy for ovarian cancer |
| Q33798999 | Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions |
| Q99554802 | Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models |
| Q34287982 | Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer |
| Q39106841 | Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage |
| Q37269217 | Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines |
| Q28083849 | Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes |
| Q47716584 | Contemporary Management of Localized Resectable Pancreatic Cancer |
| Q48601126 | Continuous genetic recording with self-targeting CRISPR-Cas in human cells |
| Q36455184 | Coordination of DNA repair by NEIL1 and PARP-1: a possible link to aging |
| Q92133931 | Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer |
| Q36195450 | Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib |
| Q50088520 | Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer. |
| Q27679467 | Crystal Structure of Human ADP-ribose Transferase ARTD15/PARP16 Reveals a Novel Putative Regulatory Domain |
| Q27666573 | Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA: STRUCTURAL AND FUNCTIONAL INSIGHTS INTO DNA-DEPENDENT PARP-1 ACTIVITY |
| Q59795829 | Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening |
| Q35684568 | Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. |
| Q26745453 | Current and emerging therapies in unresectable and recurrent gastric cancer |
| Q38019027 | Current and future management strategies for relapsed or progressive hepatoblastoma |
| Q47155297 | Current status of poly(ADP-ribose) polymerase inhibitors and future directions. |
| Q36200224 | Cytokine-mediated β-cell damage in PARP-1-deficient islets. |
| Q26776513 | DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer |
| Q27005594 | DNA Damage and Pulmonary Hypertension |
| Q64078978 | DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors |
| Q55399645 | DNA damage repair in ovarian cancer: unlocking the heterogeneity. |
| Q37990061 | DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. |
| Q34044319 | DNA damage triggers SAF-A and RNA biogenesis factors exclusion from chromatin coupled to R-loops removal. |
| Q64066898 | DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD depletion in experimental atrial fibrillation |
| Q88337377 | DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression |
| Q34360500 | DNA double-strand break signaling and human disorders |
| Q35097944 | DNA ligase III acts as a DNA strand break sensor in the cellular orchestration of DNA strand break repair |
| Q38061847 | DNA repair dysregulation from cancer driver to therapeutic target |
| Q26740256 | DNA repair mechanisms and their clinical impact in glioblastoma |
| Q35531287 | DNA repair mechanisms in cancer development and therapy |
| Q26768679 | DNA repair targeted therapy: The past or future of cancer treatment? |
| Q42289851 | DNA single-strand break-induced DNA damage response causes heart failure |
| Q34464748 | DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes |
| Q33871913 | Damage site chromatin: open or closed? |
| Q34077953 | Decreased SIRT2 activity leads to altered microtubule dynamics in oxidatively-stressed neuronal cells: implications for Parkinson's disease. |
| Q63071454 | Defective homologous recombination DNA repair as therapeutic target in advanced chordoma |
| Q36257738 | Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy |
| Q39037299 | Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer |
| Q27347956 | Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. |
| Q90066525 | Developing effective combination therapy for pancreatic cancer: An overview |
| Q46097861 | Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies. |
| Q34380368 | Development of synthetic lethality anticancer therapeutics |
| Q100736939 | Development of synthetic lethality in cancer: molecular and cellular classification |
| Q38874006 | Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells |
| Q35782629 | Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities |
| Q34978267 | Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells |
| Q35922047 | Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus |
| Q36699773 | Differential responses of pancreatic β-cells to ROS and RNS. |
| Q52639510 | Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib. |
| Q27684311 | Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors |
| Q41846529 | Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). |
| Q38644956 | Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy |
| Q89997426 | Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation |
| Q33952953 | Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner |
| Q47687132 | Doxycycline synergizes with doxorubicin to inhibit the proliferation of castration-resistant prostate cancer cells |
| Q38779989 | Drug Monographs: Olaratumab and Rucaparib |
| Q38161343 | Drug treatment of cancer cell lines: a way to select for cancer stem cells? |
| Q36460391 | Dual roles of PARP-1 promote cancer growth and progression |
| Q90680247 | EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma |
| Q47830097 | Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke. |
| Q64990906 | Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. |
| Q47116685 | Effects of yak-activated protein on hematopoiesis and related cytokines in radiation-induced injury in mice |
| Q34092219 | Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes |
| Q37876194 | Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer |
| Q26741300 | Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q47107471 | Emerging treatment options for ovarian cancer: focus on rucaparib |
| Q37645201 | Emerging treatment options in the management of non-small cell lung cancer. |
| Q64974925 | Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. |
| Q35763155 | Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. |
| Q60910649 | Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent |
| Q26745956 | Evaluation of the methods to identify patients who may benefit from PARP inhibitor use |
| Q39486283 | Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. |
| Q36353993 | Evidence for abasic site sugar phosphate-mediated cytotoxicity in alkylating agent treated Saccharomyces cerevisiae |
| Q34306599 | Evolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells |
| Q38466329 | Exploiting replicative stress to treat cancer |
| Q37818230 | Exploration of synthetic lethal interactions as cancer drug targets |
| Q36317201 | Exploring the therapeutic space around NAD+. |
| Q87116290 | Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients |
| Q38423284 | Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer |
| Q51887319 | Expression of antioxidant defense and poly(ADP-ribose) polymerase-1 in rat developing Sertoli cells. |
| Q24615499 | Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro |
| Q92002816 | Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets |
| Q96303456 | First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor |
| Q37452775 | Fish oil suppresses cell growth and metastatic potential by regulating PTEN and NF-κB signaling in colorectal cancer |
| Q39063397 | Flow signaling and atherosclerosis |
| Q36117690 | Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control |
| Q24293084 | Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation |
| Q33649584 | Functional Aspects of PARP1 in DNA Repair and Transcription |
| Q26744796 | Functions of PARylation in DNA Damage Repair Pathways |
| Q37826274 | Future directions in castrate-resistant prostate cancer therapy. |
| Q47949771 | GBM radiosensitizers: dead in the water…or just the beginning? |
| Q38965229 | Gambogic Acid and Its Role in Chronic Diseases. |
| Q50917719 | Generation of Dose-Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations. |
| Q35788495 | Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer |
| Q37181520 | Genetic variation of the brca1 and brca2 genes in macedonian patients |
| Q47177974 | Genome-wide association study of carcass weight in commercial Hanwoo cattle. |
| Q36144711 | Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. |
| Q38115576 | Genomic instability in multiple myeloma: mechanisms and therapeutic implications |
| Q46406409 | Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression |
| Q37269005 | Genomic landscape of DNA repair genes in cancer |
| Q47115540 | Genomic regression analysis of coordinated expression |
| Q41887078 | Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers |
| Q38124090 | HIV integrase inhibitors: 20-year landmark and challenges |
| Q36839571 | Harnessing synthetic lethal interactions in anticancer drug discovery |
| Q38959156 | Hepatocyte-specific high-mobility group box 1 deletion worsens the injury in liver ischemia/reperfusion: a role for intracellular high-mobility group box 1 in cellular protection |
| Q36171886 | Herpes simplex virus 1 infection activates poly(ADP-ribose) polymerase and triggers the degradation of poly(ADP-ribose) glycohydrolase |
| Q40432109 | High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer |
| Q37050088 | High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. |
| Q33759591 | High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control |
| Q42015179 | High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors |
| Q34221822 | Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells |
| Q34134483 | Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers |
| Q38170081 | How do I kill thee? Let me count the ways: p53 regulates PARP-1 dependent necrosis |
| Q58699202 | Human papillomavirus and genome instability: from productive infection to cancer |
| Q36621346 | Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells |
| Q52683821 | Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes. |
| Q90088006 | Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer |
| Q35180889 | Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage |
| Q33581909 | Imaging the DNA damage response with PET and SPECT |
| Q35882189 | Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents |
| Q26850193 | Improving the efficacy of chemoradiation with targeted agents |
| Q38293619 | In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment |
| Q37580300 | Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer |
| Q34121535 | Induction of pluripotent stem cells from human third molar mesenchymal stromal cells |
| Q37122690 | Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer |
| Q64067121 | Inhibition as a Novel Therapeutic Target for Keloid Disease |
| Q34769158 | Inhibition of DNA damage repair by artificial activation of PARP with siDNA. |
| Q43238750 | Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells |
| Q34299288 | Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2. |
| Q34125932 | Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse |
| Q64883630 | Integrating the DNA damage and protein stress responses during cancer development and treatment. |
| Q28388726 | Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research |
| Q21245636 | Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry |
| Q39168925 | Investigational drugs for the treatment of cervical cancer. |
| Q39096405 | Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition |
| Q34993640 | JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib |
| Q36211466 | KIFC1 is a novel potential therapeutic target for breast cancer. |
| Q39142926 | Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation |
| Q35106254 | KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma |
| Q28393344 | Kinetics and thermodynamics of zinc(II) and arsenic(III) binding to XPA and PARP-1 zinc finger peptides |
| Q34343255 | Kinetics of endogenous mouse FEN1 in base excision repair. |
| Q37687396 | LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors |
| Q40244416 | LRP1 Regulates Retinal Angiogenesis by Inhibiting PARP-1 Activity and Endothelial Cell Proliferation |
| Q44660774 | Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 induce different age-related metabolic profiles revealed by 1H-NMR spectroscopy in urine and feces of mice. |
| Q36150083 | Large-scale preparation and characterization of poly(ADP-ribose) and defined length polymers |
| Q30663823 | Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). |
| Q92563210 | Loss of PARP-1 attenuates diabetic arteriosclerotic calcification via Stat1/Runx2 axis |
| Q28290788 | Luring BRCA1 to the scene of the crime |
| Q94076875 | MRL-45696减轻2型糖尿病大鼠心肌缺血再灌注后的DNA损伤 |
| Q37712074 | Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase. |
| Q34982828 | Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator |
| Q35155460 | Management options in triple-negative breast cancer |
| Q36446799 | Mapping the effects of drugs on the immune system |
| Q37956668 | Mass spectrometry-based functional proteomics of poly(ADP-ribose) polymerase-1. |
| Q47949142 | Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging |
| Q38161574 | Mechanisms and potential therapeutic targets in allergic inflammation: recent insights. |
| Q48181461 | Melatonin regulates PARP1 to control the senescence-associated secretory phenotype (SASP) in human fetal lung fibroblast cells |
| Q36164842 | Metabolic responses induced by DNA damage and poly (ADP-ribose) polymerase (PARP) inhibition in MCF-7 cells |
| Q33904600 | Metabolomics of ApcMin/+ mice genetically susceptible to intestinal cancer |
| Q42557466 | MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1 |
| Q49787194 | MicroRNA-379-5p is associate with biochemical premature ovarian insufficiency through PARP1 and XRCC6. |
| Q33808938 | MicroRNAs Modulate Oxidative Stress in Hypertension through PARP-1 Regulation |
| Q57106460 | MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers |
| Q30570945 | Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives |
| Q26765241 | Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer |
| Q37999690 | Molecular mechanisms and potential functions of histone demethylases |
| Q59540864 | Molecular mechanisms and potential functions of histone demethylases |
| Q38010801 | Molecular mechanisms of temozolomide resistance in glioblastoma multiforme |
| Q39497723 | Molecular pathways: targeting PARP in cancer treatment |
| Q34306334 | Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement |
| Q47737258 | NAD+ Deficits in Age-Related Diseases and Cancer |
| Q50128435 | NAD+ in Aging: Molecular Mechanisms and Translational Implications |
| Q90438582 | NAD+ in Brain Aging and Neurodegenerative Disorders |
| Q61796965 | NADP is an endogenous PARP inhibitor in DNA damage response and tumor suppression |
| Q38818143 | Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment |
| Q90397109 | Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells |
| Q47930214 | Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons |
| Q35779661 | New PARP targets for cancer therapy |
| Q28486776 | New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules |
| Q38021692 | New biomarkers and targets in pancreatic cancer and their application to treatment |
| Q38020082 | New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs |
| Q38024191 | New readers and interpretations of poly(ADP-ribosyl)ation |
| Q38180769 | New strategies for the treatment of ovarian cancer |
| Q26745614 | New treatment option for ovarian cancer: PARP inhibitors |
| Q34104143 | Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells |
| Q64090670 | Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation |
| Q36827491 | Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. |
| Q34602683 | Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. |
| Q92129186 | Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q45365306 | Novel poly (ADP-ribose) polymerase 1 binding motif in hepatitis B virus core promoter impairs DNA damage repair |
| Q35011473 | Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. |
| Q26851765 | Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition |
| Q36472478 | Nuclear ULK1 promotes cell death in response to oxidative stress through PARP1 |
| Q30425591 | Nuclear-cytoplasmic trafficking of NTF2, the nuclear import receptor for the RanGTPase, is subjected to regulation |
| Q38231610 | Nucleic acid sensing and beyond: virtues and vices of high-mobility group box 1. |
| Q90063180 | Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling |
| Q44846367 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study |
| Q26797166 | Olaparib in the management of ovarian cancer |
| Q38101861 | Olaparib: a promising PARP inhibitor in ovarian cancer therapy |
| Q37990715 | On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. |
| Q38756293 | On glioblastoma and the search for a cure: where do we stand? |
| Q36038823 | Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils |
| Q35685920 | Oncogenic activation of ERG: A predominant mechanism in prostate cancer |
| Q35903928 | Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma |
| Q35000546 | Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model |
| Q38235868 | Organelle-specific initiation of cell death |
| Q41472115 | Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics |
| Q28552235 | Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations |
| Q38682200 | Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. |
| Q60950302 | Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment |
| Q55049874 | Oxidative stress in female cancers. |
| Q38022936 | Oxidized base damage and single-strand break repair in mammalian genomes: role of disordered regions and posttranslational modifications in early enzymes |
| Q39791288 | PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2 |
| Q40640808 | PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. |
| Q89659933 | PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation |
| Q26768661 | PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives |
| Q35993616 | PARP Inhibitors for the Treatment and Prevention of Breast Cancer |
| Q92164257 | PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca" |
| Q39328164 | PARP Inhibitors in Prostate Cancer |
| Q92257452 | PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development |
| Q37607283 | PARP Inhibitors in Reproductive System Cancers: Current Use and Developments |
| Q36901517 | PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells |
| Q38831984 | PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials |
| Q54471607 | PARP inhibition attenuates histopathological lesion in ischemia/reperfusion renal mouse model after cold prolonged ischemia. |
| Q34000773 | PARP inhibition delays progression of mitochondrial encephalopathy in mice. |
| Q27303034 | PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier |
| Q36740692 | PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. |
| Q39425287 | PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. |
| Q39169663 | PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells |
| Q50980480 | PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. |
| Q28741688 | PARP inhibitor treatment in ovarian and breast cancer |
| Q38326336 | PARP inhibitors |
| Q28071345 | PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions |
| Q38180762 | PARP inhibitors for anticancer therapy |
| Q38078993 | PARP inhibitors in cancer therapy: an update. |
| Q38194324 | PARP inhibitors in ovarian cancer: current status and future promise |
| Q49723005 | PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer |
| Q37947887 | PARP inhibitors--current status and the walk towards early breast cancer |
| Q33579740 | PARP inhibitors: its role in treatment of cancer |
| Q37668511 | PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |
| Q49385666 | PARP-1 Inhibition Rescues Short Lifespan in Hyperglycemic C. Elegans And Improves GLP-1 Secretion in Human Cells. |
| Q46114975 | PARP-1 Variant Rs1136410 Confers Protection against Coronary Artery Disease in a Chinese Han Population: A Two-Stage Case-Control Study Involving 5643 Subjects. |
| Q37942024 | PARP-1 and PARP-2: New players in tumour development. |
| Q34030005 | PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair in vitro |
| Q35871546 | PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma |
| Q34421470 | PARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells |
| Q38075305 | PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis |
| Q40120413 | PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population |
| Q47604328 | PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors |
| Q38792223 | PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair |
| Q33617922 | PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models |
| Q27312275 | PARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function. |
| Q92627360 | PARP1 gene polymorphisms and neuroblastoma susceptibility in Chinese children |
| Q43042008 | PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs |
| Q37293979 | PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. |
| Q37688982 | PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. |
| Q98728929 | PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response |
| Q39231132 | PARP1 represses PAP and inhibits polyadenylation during heat shock |
| Q37701295 | PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage |
| Q55615916 | PARP1-dependent recruitment of the FBXL10-RNF68-RNF2 ubiquitin ligase to sites of DNA damage controls H2A.Z loading. |
| Q58699735 | PARP12 (ARTD12) suppresses hepatocellular carcinoma metastasis through interacting with FHL2 and regulating its stability |
| Q47833710 | PARPi potentiates with current conventional therapy in MLL leukemia |
| Q34346449 | PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging |
| Q26859010 | PARPs and the DNA damage response |
| Q39644716 | PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors |
| Q97540196 | Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor |
| Q38592167 | Pancreatic cancer: BRCA mutation and personalized treatment |
| Q59281988 | Parp-1genetic ablation inEla-mycmice unveils novel roles for Parp-1 in pancreatic cancer |
| Q30547326 | Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss |
| Q38200674 | Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities |
| Q36117886 | Pathophysiology of perinatal asphyxia: can we predict and improve individual outcomes? |
| Q39226179 | Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. |
| Q54977914 | Persistent 3'-phosphate termini and increased cytotoxicity of radiomimetic DNA double-strand breaks in cells lacking polynucleotide kinase/phosphatase despite presence of an alternative 3'-phosphatase. |
| Q92133308 | Pharmacologic Ascorbate Primes Pancreatic Cancer Cells for Death by Rewiring Cellular Energetics and Inducing DNA Damage |
| Q64236616 | Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials |
| Q49906566 | Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies |
| Q33439705 | Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers |
| Q26858894 | Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation |
| Q34982593 | Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. |
| Q41217822 | Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms |
| Q90677069 | Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond |
| Q90263734 | Poly (ADP-Ribose) Polymerase-1 (PARP1) Deficiency and Pharmacological Inhibition by Pirenzepine Protects From Cisplatin-Induced Ototoxicity Without Affecting Antitumor Efficacy |
| Q42402995 | Poly (ADP-Ribose) Polymerase-1 causes mitochondrial damage and neuron death mediated by Bnip3, J Neurosci. 2014 Nov 26;34(48):15975-87. |
| Q37996432 | Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment |
| Q34308770 | Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer |
| Q33688658 | Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers |
| Q35895214 | Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. |
| Q41143476 | Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma |
| Q36130936 | Poly (ADP-ribose) transferase/polymerase-1-deficient mice resistant to age-dependent decrease in β-cell proliferation |
| Q26800013 | Poly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and Tumorogenesis |
| Q64085548 | Poly(ADP-Ribose) Polymerases in Plants and Their Human Counterparts: Parallels and Peculiarities |
| Q35112912 | Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. |
| Q90478703 | Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy |
| Q39041714 | Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation |
| Q38915776 | Poly(ADP-ribose) glycohydrolase silencing down-regulates TCTP and Cofilin-1 associated with metastasis in benzo(a)pyrene carcinogenesis |
| Q35639790 | Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1). |
| Q38134049 | Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications |
| Q36105500 | Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors |
| Q34946954 | Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells |
| Q35608666 | Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? |
| Q42837099 | Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro |
| Q37727996 | Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics |
| Q38212771 | Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma |
| Q33947014 | Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. |
| Q37773040 | Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications |
| Q48445649 | Poly(ADP-ribose) polymerase-1 causes mitochondrial damage and neuron death mediated by Bnip3. |
| Q24595686 | Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure |
| Q27321704 | Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions |
| Q33851843 | Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality |
| Q35514172 | Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury |
| Q50977186 | Poly(ADP-ribose) polymerases regulate cell division and development in Arabidopsis roots. |
| Q39551829 | Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells |
| Q41229337 | Poly(ADP-ribose) regulates post-transcriptional gene regulation in the cytoplasm. |
| Q38379602 | Poly(ADP-ribose)--a unique natural polymer structural features, biological role and approaches to the chemical synthesis |
| Q41867404 | Poly(ADP-ribose)-binding promotes Exo1 damage recruitment and suppresses its nuclease activities |
| Q38155805 | Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response |
| Q38895280 | Poor prognosis of constitutive γ-H2AX expressing triple-negative breast cancers is associated with telomere length. |
| Q53529517 | Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. |
| Q35755464 | Post-Translational Modifications of Kaposi's Sarcoma-Associated Herpesvirus Regulatory Proteins - SUMO and KSHV |
| Q37139138 | Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins |
| Q38846185 | Post-translational modifications in mitochondria: protein signaling in the powerhouse |
| Q38137764 | Predictive biomarkers for cancer therapy with PARP inhibitors. |
| Q64951000 | Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer. |
| Q36284245 | Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis |
| Q35891063 | Protective Effect of Lycium ruthenicum Murr. Against Radiation Injury in Mice |
| Q35517295 | Protective effects of (E)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeine against hydrogen peroxide-induced injury in PC12 cells |
| Q40465701 | Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. |
| Q37324094 | Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue. |
| Q38255037 | Proteomics approaches to identify mono-(ADP-ribosyl)ated and poly(ADP-ribosyl)ated proteins. |
| Q50898029 | Purification of DNA Damage-Dependent PARPs from E. coli for Structural and Biochemical Analysis. |
| Q50898043 | Purification of Recombinant Human PARP-3. |
| Q43186594 | Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology |
| Q39043296 | Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells |
| Q37227952 | Quantification of cellular poly(ADP-ribosyl)ation by stable isotope dilution mass spectrometry reveals tissue- and drug-dependent stress response dynamics |
| Q52568842 | Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. |
| Q36101178 | Quantitative analysis of WRN exonuclease activity by isotope dilution mass spectrometry |
| Q36228488 | Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress |
| Q47156447 | RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells |
| Q55504424 | RIOK1 kinase activity is required for cell survival irrespective of MTAP status. |
| Q64988464 | ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. |
| Q35141185 | Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells |
| Q35764111 | Radioiodinated PARP1 tracers for glioblastoma imaging |
| Q26752579 | Radioresistance of Brain Tumors |
| Q90346203 | Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas |
| Q34092001 | Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888. |
| Q90320698 | Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study |
| Q34924914 | Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis |
| Q33603605 | Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition |
| Q39116332 | Reduced ADP-ribosylation by PARP1 natural polymorphism V762A and by PARP1 inhibitors enhance Hepatitis B virus replication |
| Q28384999 | Reduction of arsenite-enhanced ultraviolet radiation-induced DNA damage by supplemental zinc |
| Q24294656 | Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4 |
| Q26822957 | Repair of oxidative DNA damage and cancer: recent progress in DNA base excision repair |
| Q93355907 | Repair pathway for PARP-1 DNA-protein crosslinks |
| Q38365123 | Replication fork reversal in eukaryotes: from dead end to dynamic response |
| Q38069879 | Reprogramming cellular events by poly(ADP-ribose)-binding proteins |
| Q37684589 | Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition |
| Q42177520 | Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. |
| Q35119267 | Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation |
| Q34903773 | Reverse differentiation as a gene filtering tool in genome expression profiling of adipogenesis for fat marker gene selection and their analysis |
| Q28508150 | Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination |
| Q96954202 | Role of DNA repair defects in predicting immunotherapy response |
| Q33899993 | Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases |
| Q37502859 | SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism |
| Q34291657 | Saccharomyces cerevisiae as a model system to study the response to anticancer agents |
| Q38519719 | Safety evaluation of olaparib for treating ovarian cancer |
| Q28554210 | Sam68 Is Required for DNA Damage Responses via Regulating Poly(ADP-ribosyl)ation |
| Q37123861 | Sam68/KHDRBS1 is critical for colon tumorigenesis by regulating genotoxic stress-induced NF-κB activation |
| Q34983549 | Secondary mutations of BRCA1/2 and drug resistance |
| Q52401743 | Selective targeting of PARP-1 zinc finger recognition domains with Au(iii) organometallics. |
| Q37725418 | Sensitizing thermochemotherapy with a PARP1-inhibitor. |
| Q46245748 | Serendipitous discovery of a prodrug of a PARP-1 inhibitor |
| Q41348897 | Serine ADP-ribosylation reversal by the hydrolase ARH3 |
| Q21133568 | Single cell analysis of drug distribution by intravital imaging |
| Q30650918 | Single cell resolution in vivo imaging of DNA damage following PARP inhibition |
| Q34592125 | Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. |
| Q94073889 | Sirtuins in Renal Health and Disease |
| Q45389826 | Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome |
| Q36545280 | Site-specific noncovalent interaction of the biopolymer poly(ADP-ribose) with the Werner syndrome protein regulates protein functions. |
| Q36811784 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? |
| Q89956053 | Small-molecule drug repurposing to target DNA damage repair and response pathways |
| Q38151570 | Somatic alterations as the basis for resistance to targeted therapies |
| Q39347239 | Sstr2A: a relevant target for the delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors |
| Q37623863 | Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib |
| Q27679074 | Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1 |
| Q24299239 | Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease |
| Q40220408 | Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone |
| Q27004584 | Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases |
| Q48219721 | Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors. |
| Q59137850 | Structure-based mechanism of action of a viral poly(ADP-ribose) polymerase 1-interacting protein facilitating virus replication |
| Q26777131 | Successes and Challenges of PARP Inhibitors in Cancer Therapy |
| Q36092308 | Suppressive regulation of KSHV RTA with O-GlcNAcylation |
| Q36315855 | Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. |
| Q36798051 | Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer |
| Q39590473 | Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. |
| Q90143376 | Synthesis of Poly(ADP-ribose) Monomer Containing 2'-O-α-D-Ribofuranosyl Adenosine |
| Q34210627 | Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors |
| Q59129210 | Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors |
| Q37226478 | Synthetic genetic targeting of genome instability in cancer. |
| Q47160964 | Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis |
| Q37092210 | Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors |
| Q52773665 | Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. |
| Q38709651 | Synthetic lethality and cancer. |
| Q34536666 | Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies. |
| Q24317056 | Systematic identification of molecular links between core and candidate genes in breast cancer |
| Q38711389 | Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells. |
| Q34037146 | TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death |
| Q51038790 | TS-Chemscore, a Target-Specific Scoring Function, Significantly Improves the Performance of Scoring in Virtual Screening. |
| Q64235490 | Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors |
| Q38063790 | Tankyrase-targeted therapeutics: expanding opportunities in the PARP family |
| Q48251246 | Target engagement imaging of PARP inhibitors in small-cell lung cancer. |
| Q58293218 | Target validation using in-cell small molecule clickable imaging probes |
| Q34878868 | Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q38009760 | Targeted therapy for triple-negative breast cancer: where are we? |
| Q52657032 | Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. |
| Q27023204 | Targeting DNA damage response in cancer therapy |
| Q89777366 | Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints |
| Q39393235 | Targeting DNA repair and replication stress in the treatment of ovarian cancer. |
| Q34015040 | Targeting DNA repair pathways for cancer treatment: what's new? |
| Q51776565 | Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule. |
| Q41136568 | Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion. |
| Q91912549 | Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia |
| Q64061652 | Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies |
| Q34204660 | Targeting poly(ADP-ribose) polymerase activity for cancer therapy |
| Q34055827 | Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer |
| Q37506032 | Targeting the LKB1 tumor suppressor |
| Q33657519 | Targeting tumor suppressor networks for cancer therapeutics |
| Q38191794 | Targeting tumour-supportive cellular machineries in anticancer drug development |
| Q35665399 | Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients |
| Q85089787 | The "luxury" of second malignancies |
| Q34552582 | The 3'-5' DNA exonuclease TREX1 directly interacts with poly(ADP-ribose) polymerase-1 (PARP1) during the DNA damage response |
| Q28550106 | The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response |
| Q92408468 | The Chemopreventive Activity of Indonesia Medicinal Plants Targeting on Hallmarks of Cancer |
| Q37977004 | The DNA damage response and cancer therapy |
| Q37322627 | The Effect of Poly(ADP-ribose) Polymerase-1 Gene 3'Untranslated Region Polymorphism in Colorectal Cancer Risk among Saudi Cohort. |
| Q38142158 | The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. |
| Q57816662 | The MacroH2A1.1 - PARP1 Axis at the Intersection Between Stress Response and Metabolism |
| Q38047182 | The NAD metabolome--a key determinant of cancer cell biology |
| Q42826404 | The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines |
| Q35255891 | The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest |
| Q55037005 | The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. |
| Q37770152 | The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets |
| Q47111141 | The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells |
| Q39187205 | The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair |
| Q37394040 | The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells |
| Q21129302 | The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies |
| Q89994373 | The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond |
| Q33897970 | The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction |
| Q38894924 | The assessment of an in-vitro model for evaluating the role of PARP in ethanol-mediated hepatotoxicity |
| Q35622211 | The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice |
| Q40354602 | The conserved macrodomains of the non-structural proteins of Chikungunya virus and other pathogenic positive strand RNA viruses function as mono-ADP-ribosylhydrolases |
| Q36752056 | The development of PARP inhibitors in ovarian cancer: from bench to bedside |
| Q35992296 | The dual action of poly(ADP-ribose) polymerase -1 (PARP-1) inhibition in HIV-1 infection: HIV-1 LTR inhibition and diminution in Rho GTPase activity |
| Q41425376 | The histone variant macroH2A1.1 is recruited to DSBs through a mechanism involving PARP1. |
| Q50283539 | The interaction of a single-nucleotide polymorphism with age on response to interferon-α and ribavirin therapy in female patients with hepatitis C infection |
| Q63384128 | The interplay between BRCA1 and 53BP1 influences death, aging, senescence and cancer |
| Q50187396 | The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells |
| Q64105526 | The non-homologous end-joining activity is required for Fanconi anemia fetal HSC maintenance |
| Q89004561 | The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer |
| Q35534509 | The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy |
| Q38109700 | The recognition and removal of cellular poly(ADP-ribose) signals. |
| Q35055739 | The redox basis of epigenetic modifications: from mechanisms to functional consequences. |
| Q38064172 | The role of BRCA1 in DNA double-strand repair: past and present |
| Q27002399 | The role of PARP in DNA repair and its therapeutic exploitation |
| Q38015737 | The role of PARP1 in the DNA damage response and its application in tumor therapy |
| Q47287095 | The role of poly ADP-ribosylation in the first wave of DNA damage response. |
| Q37925127 | The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions |
| Q90381105 | The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review |
| Q27010084 | The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy |
| Q35232277 | The ups and downs of DNA repair biomarkers for PARP inhibitor therapies |
| Q95841163 | Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors |
| Q35845484 | Therapeutic strategies in epithelial ovarian cancer |
| Q39386006 | Topoisomerase I poisoning results in PARP-mediated replication fork reversal |
| Q33438344 | Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis |
| Q35053261 | Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? |
| Q28070128 | Transcriptional and Posttranslational Regulation of Nucleotide Excision Repair: The Guardian of the Genome against Ultraviolet Radiation |
| Q64977994 | Translational research in radiation-induced DNA damage signaling and repair. |
| Q39005112 | Transport and killing mechanism of a novel camptothecin-deoxycholic acid derivate on hepatocellular carcinoma cells |
| Q34309488 | Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors |
| Q89647010 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response |
| Q34331406 | Treatment options for patients with triple-negative breast cancer |
| Q95260148 | Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future |
| Q26745673 | Trial watch - inhibiting PARP enzymes for anticancer therapy |
| Q37793824 | Triple-negative breast cancer: disease entity or title of convenience? |
| Q36689103 | Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications |
| Q35447633 | UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation |
| Q63976958 | Unanchored tri-NEDD8 inhibits PARP-1 to protect from oxidative stress-induced cell death |
| Q51761205 | Uncoupling of RAD51 focus formation and cell survival after replication fork stalling in RAD51D null CHO cells. |
| Q38769421 | Unravelling the biology of SCLC: implications for therapy |
| Q38659573 | Use of Inosine Monophosphate Dehydrogenase Activity Assay to Determine the Specificity of PARP-1 Inhibitors |
| Q28071541 | Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic |
| Q57111690 | Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? |
| Q61136635 | ZNF506-dependent positive feedback loop regulates H2AX signaling after DNA damage |
| Q92728797 | [New Advances in the Treatment for Small Cell Lung Cancer] |
| Q51841208 | [Recent Advances and Future Strategies for Small Cell Lung Cancer]. |
| Q42378530 | miR-708-5p: a microRNA with emerging roles in cancer |
Search more.